ANAB ANAPTYSBIO, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1370053 · Fiscal year ends 06/30
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY107.7%
TTM net income YoY81.0%
TTM EPS YoY78.1%
Revenue 3-yr CAGR179.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin35.9%
Net margin-11.5%
FCF margin1.9%
EBITDA margin36.0%
Returns
ROE-114.6%
ROA-7.1%
ROIC (approx.)—
Asset turnover0.62x
Leverage & solvency
Liabilities / assets96.1%
Debt / equity0.00x
Current ratio7.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.17x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-09-30 | 2026Q4*2026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $30.27M | $27.49M | $25.56M | $108.25M | $76.32M | $22.26M | $27.77M | $43.11M |
| R&D expense | — | — | $33.99M | $25.56M | $31.41M | $37.82M | $41.18M | $42.59M |
| SG&A expense | $11.64M | -$2.81M | $26.20M | $15.79M | $1.08M | $10.61M | $14.13M | $10.19M |
| Operating income | $19.91M | $66.96M | -$34.64M | $66.90M | $77.27M | -$26.17M | -$27.54M | -$9.67M |
| Pretax income | $3.27M | $47.75M | -$52.84M | $49.70M | $56.62M | -$38.59M | -$39.28M | -$21.79M |
| Income tax | -$608,000 | -$181.49M | $40,000 | $81,000 | $269,000 | $39,000 | $44,000 | -$6,000 |
| Net income | $3.88M | $183.88M | -$52.88M | $49.61M | $15.11M | -$38.63M | -$39.33M | -$21.78M |
| EBITDA | $19.91M | $66.84M | -$34.51M | $67.03M | $77.28M | -$26.03M | -$27.39M | -$9.53M |
| EPS (basic) | 0.13 | — | -1.84 | — | 0.54 | -1.34 | -1.28 | — |
| EPS (diluted) | 0.11 | — | -1.84 | — | 0.52 | -1.34 | -1.28 | — |
| Weighted avg. shares (diluted) | 35.07M | — | 28.69M | — | 29.02M | 28.81M | 30.64M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $135.39M | $133.83M | $248.47M | $138.20M | $9.83M | $0 | $98.64M | $23.08M |
| Short-term investments | $17.60M | $30.32M | $37.99M | $73.44M | $139.12M | $221.41M | $241.30M | $262.29M |
| Receivables | $30.49M | $25.63M | $25.75M | $33.85M | $75.69M | $21.42M | $17.88M | $40.77M |
| Current assets | $188.37M | $198.43M | $316.11M | $350.25M | $330.65M | $291.91M | $363.11M | $431.88M |
| PP&E, net | $97,000 | $102,000 | $1.28M | $111,000 | $1.50M | $1.63M | $1.74M | $131,000 |
| Total assets | $307.04M | $316.98M | $329.68M | $364.39M | $353.10M | $335.25M | $422.05M | $483.83M |
| Current liabilities | $22.42M | $35.35M | $41.70M | $38.62M | $38.10M | $35.53M | $44.04M | $45.43M |
| Total liabilities | $286.22M | $306.40M | $316.94M | $327.19M | $382.51M | $379.98M | $388.03M | $412.97M |
| Shareholders' equity | $20.82M | $10.59M | $12.75M | $37.21M | -$29.42M | -$44.73M | $34.02M | $70.87M |
| Shares outstanding | 29.94M | 29.73M | 29.03M | 28.02M | 27.58M | 27.97M | 30.39M | 30.47M |
| Cash flow statement | ||||||||
| Operating cash flow | -$9.54M | -$26.64M | -$25.92M | $98.00M | -$27.36M | -$40.24M | -$10.70M | -$66.67M |
| Capital expenditure | — | — | $17,000 | $1,000 | $12,000 | $39,000 | $35,000 | $263,000 |
| Free cash flow | — | — | -$25.94M | $98.00M | -$27.37M | -$40.28M | -$10.73M | -$66.94M |
| Investing cash flow | $12.59M | $7.56M | $34.98M | $73.50M | $47.58M | $36.40M | $14.85M | -$29.40M |
| Financing cash flow | -$1.48M | -$95.56M | $1.21M | -$43.13M | -$10.39M | -$50.50M | -$28.59M | $27.57M |
| Depreciation & amortization | $5,000 | -$121,000 | $130,000 | $131,000 | $4,000 | $142,000 | $146,000 | $145,000 |
| Stock-based compensation | $3.21M | -$5.90M | $14.22M | $8.51M | $207,000 | $9.24M | $9.17M | $8.18M |
| Share buybacks | $0 | $0 | $0 | $3.38M | $9.72M | $51.10M | $4.42M | $456,000 |
Free plan shows the latest 8 periods; Pro shows all 43 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.